Novel Method development and Validation of Bortezomib in Bulk and Pharmaceutical dosage form by RP- HPLC
Abstract
A simple, rapid, precise and accurate RP-HPLC method was developed and validated for the determination of Bortezomib, in bulk and pharmaceutical dosage form. The separation is achieved on RP-HPLC using a PDA detector by incorporation of enpower 2 software with a flow rate of 1.0ml/min using a mixture of Methanol and water (15:85% v/v) as mobile phase. The column used was Hypersil C18 (4.6×150mm, 5µ) at a wave length of 284nm. The retention time of the Bortezomib was 3.515min.. The linearity of the drug was 25-125µg/m and the method precision for the determination of assay was below 2.0% RSD. The proposed method was validated and applied for the estimation of Bortezomib in quality control of bulk and pharmaceutical dosage forms.
Keywords: Bortezomib, RP-HPLC, validation.
DOI
https://doi.org/10.22270/jddt.v9i1.2259References
Dr. Kealey and P.J Haines, Analytical Chemistry, 1stedition, Bios Publisher, (2002), PP 1-7.
A.BraithWait and F.J.Smith, Chromatographic Methods, 5thedition, Kluwer Academic Publisher, (1996), PP 1-2.
Andrea Weston and Phyllisr. Brown, HPLC Principle and Practice, 1st edition, Academic press, (1997), PP 24-37.
Yuri Kazakevich and Rosario Lobrutto, HPLC for Pharmaceutical Scientists, 1stedition, Wiley Interscience A JohnWiley & Sons, Inc., Publication, (2007), PP 15-23.
Chromatography, (online). URL:http://en.wikipedia.org/wiki/Chromatography.
Meyer V.R. Practical High-Performance Liquid Chromatography, 4 Ed. England, John Wiley & Sons Ltd, (2004), PP 7-8.
Sahajwalla CG a new drug development, vol 141, Marcel Dekker Inc., New York, (2004), PP 421–426.
Introduction to Column. (Online),URL:http://amitpatel745.topcities.com/index_files/study/co lumn care.pdf
Detectors used in HPLC (online )URL:http://wiki.answers.com/Q/What_detectors_are_used_ in_HPLC
Detectors (online) ,URL:http://hplc.chem.shu.edu/NEW/HPLC_Book/Detectors/det_uvda.ht ml
URL:http://businesswireindia.com/news/news-details/us-fda-approves-takedas-ninlaro- Bortezomib-first-only-oral-proteasome-inhibitor-treat-multiple-myeloma/46254
URL:www.medkoo.com
Published
Abstract Display: 980 
PDF Downloads: 1124 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.